Lumos Pharma, Inc. (NASDAQ:LUMO) Short Interest Down 39.3% in November

Lumos Pharma, Inc. (NASDAQ:LUMO) was the recipient of a large decline in short interest in November. As of November 30th, there was short interest totalling 54,300 shares, a decline of 39.3% from the November 15th total of 89,500 shares. Approximately 1.0% of the company’s shares are short sold. Based on an average daily volume of 83,800 shares, the short-interest ratio is presently 0.6 days.

Lumos Pharma Stock Performance

NASDAQ LUMO remained flat at $4.34 during trading hours on Thursday. The company had a trading volume of 481,687 shares, compared to its average volume of 57,302. The stock has a 50 day moving average price of $4.20 and a 200 day moving average price of $3.21. Lumos Pharma has a 52 week low of $1.37 and a 52 week high of $4.58. The company has a market capitalization of $37.54 million, a P/E ratio of -1.01 and a beta of 0.74.

Hedge Funds Weigh In On Lumos Pharma

A hedge fund recently raised its stake in Lumos Pharma stock. Private Advisor Group LLC boosted its stake in shares of Lumos Pharma, Inc. (NASDAQ:LUMO) by 2,380.6% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 744,513 shares of the company’s stock after purchasing an additional 714,500 shares during the period. Private Advisor Group LLC owned about 9.17% of Lumos Pharma worth $2,881,000 at the end of the most recent quarter. 33.99% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several brokerages have commented on LUMO. HC Wainwright restated a “neutral” rating and issued a $4.25 price objective on shares of Lumos Pharma in a report on Friday, November 8th. EF Hutton Acquisition Co. I raised Lumos Pharma to a “strong-buy” rating in a research report on Tuesday, September 24th.

About Lumos Pharma

Lumos Pharma, Inc, a clinical-stage biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of products and therapies for people with rare diseases. Its primary product candidate is LUM-201, an oral growth hormone secretagogue ibutamoren, which is in Phase III clinical trial for the treatment of idiopathic pediatric growth hormone deficiency and other rare endocrine disorders.